Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OXiGENE gets European patent for OXi4503 in AML and other myeloid malignancies
The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted
The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted
These results will be presented in a poster presentation this evening at 7:30 PM ET at the 19th Annual Scientific Meeting and Education Day of the Society for
Initial results are being presented this weekend to clinicians convening during the American Heart Association meeting held in Chicago, including a meeting of the Association of Black Cardiologists.
The round includes initial angel and strategic investors and new investors Hillhouse Capital and CITIC Capital Partners, as well as an undisclosed blue chip U.S. public investment fund
This online proprietary platform: Emphasizes regulatory compliance of finished products Highlights quality assurance programs to prospective clients Showcases compliance to retailer programs The global economy and increased overseas
Highlights • Lusomedicamenta, together with its subsidiary, had twelve month revenues and adjusted EBITDA for non-recurring items to end September 2014 of EUR 50.7million (SEK 456.3 million) and
The Notice of Allowance is for U.S. Patent Application No. 14/230,067, "Methods for Treatment of Attention Deficit Hyperactivity Disorder", which relates to HLD-200, including its unique pharmacokinetic profile.
This award enables Integral Molecular to understand how human antibodies protect (or fail to protect) against these viruses. Using its proprietary Shotgun Mutagenesis Epitope Mapping technology, Integral Molecular
MEDI2452 is being developed by MedImmune, AstraZeneca’s biologics research and development arm. Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart
"RMD’s world-class research continues to be on the cutting edge of new technologies," said Peter Sulick, Dynasil’s Chairman of the Board, Chief Executive Officer and President. "RMD is